Drugs / rHSA/GCSF
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03246009 | Jan 2016 → Apr 2017 | breast cancer, neutropenia | Tianjin SinoBiotech Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rHSA/G-CSF | “BACKGROUND: To evaluate the efficacy and safety of recombinant human serum albumin /granulocyte colony-stimulating factor (rHSA/G-CSF) in breast cancer following receipt of...” PMID 33789616 ↗ Mar 2021 |
| Modality | Protein / enzyme biologic | “recombinant human blood clean protein/granulocyte stimulating factor fusion protein” NCT03246009 ↗ |
| Route | Subcutaneous | “Single subcutaneous injection” NCT03246009 ↗ |